Programmed death-ligand 1 copy number alterations may provid

1. Programmed death-ligand 1 copy number loss was identified as an independent risk factor for the progression of the disease 2. Copy number alteration provides additional therapy prediction on top of immunohistochemistry Evidence Rating Level: 1 (Excellent) Study Rundown: First-line treatment for non-small cell lung cancer (NSCLC) includes immune checkpoint inhibitor (ICI) therapy. To determine

Related Keywords

, Minute Medicine Inc , Rating Level , Its Impact , Benefit From Immune Checkpoint Inhibitors , Advanced Lung Cancer , Copy Number , Pd L1 , Chronic Disease , Oncology ,